AeroClean Technologies announced that independent laboratory testing has proven the company's Purgo™ air purifier is effective at reducing the viral concentration of the Omicron variant of SARS-CoV-2, the virus that causes COVID-19, which the CDC identifies as the current dominant variant in the United States. The independent testing was conducted by Innovative Bioanalysis laboratories to specifically test the efficacy of the AeroClean Purgo™ units against the Omicron variant of SARS-CoV-2 during a 60-minute test run.1 The AeroClean Purgo™ unit demonstrated a significant and quantifiable reduction in the recoverable active Omicron variant of SARS-CoV-2 in indoor air space, as shown by a 94.17% gross reduction after 30 minutes, and a 99.998% gross reduction in the highly transmissible airborne virus after 60 minutes in a room-sized chamber. AeroClean continues to lead efforts in implementing strategies for improving indoor air quality and ventilation as recommended by the White House as part of the administration's “best practices” guide for building owners and businesses.

The Company's Purgo air sanitization device has proven efficacy of a 4-log reduction rate, eliminating most harmful pathogens in the air by more than 99.99% in real-life spaces.2 As part of AeroClean's ongoing commitment to helping businesses and organizations improve IAQ for a healthier and safer world, additional efficacy testing is currently underway on viruses that are known threats to health and business continuity, such as: Influenza, Respiratory Syncytial Virus (RSV), Rhinovirus (the common cold), and other emerging airborne threats.